BBIO (BridgeBio Pharma) Shares Buyback Ratio % : -8.53 (As of Dec. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. BridgeBio Pharma's current shares buyback ratio was -8.53%.

BridgeBio Pharma Shares Buyback Ratio % Historical Data

The historical data trend for BridgeBio Pharma's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Shares Buyback Ratio % Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Shares Buyback Ratio %

Get a 7-Day Free Trial

-3.05

0.65

-19.94

-2.23

-16.24

BridgeBio Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Shares Buyback Ratio %	Get a 7-Day Free Trial															-7.88	-0.55	-6.88	-0.49	-0.51

BridgeBio Pharma Shares Buyback Ratio % Calculation

BridgeBio Pharma's Shares Buyback Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shares Buyback Ratio	=	(Shares Outstanding (EOP) (A: Dec. 2022 )	-	Shares Outstanding (EOP) (A: Dec. 2023 ))	/	Shares Outstanding (EOP) (A: Dec. 2022 )
	=	(150.626	-	175.083)	/	150.626
	=	-16.24%

BridgeBio Pharma's Shares Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

Shares Buyback Ratio	=	(Shares Outstanding (EOP) (A: Jun. 2024 )	-	Shares Outstanding (EOP) (A: Sep. 2024 ))	/	Shares Outstanding (EOP) (A: Jun. 2024 )
	=	(188.033	-	188.987)	/	188.033
	=	-0.51%

BridgeBio Pharma Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Shares Buyback Ratio %

Comparable Companies

Traded in Other Exchanges

2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Executives

Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Kkr Genetic Disorder L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301